Business
YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center
Taipei, Taiwan, Dec. 16, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA
About this update from Yd Bio Limited
[{"type":"text","content":"Taipei, Taiwan, Dec. 16, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced initiation of its latest plans for new facilities and a U.S. operations center in California to accelerate clinical development, regulatory engagement and commercial access for next‑generation diagnostics and exosome‑based therapeutics. The California operations center is currently in the site evaluation phase and the specific host city has not yet been finalized. It will support clinical collaboration, regulatory strategy and scaled operational capabilities, which is intended to assist with enabling faster clinical validation, more efficient regulatory submissions and improved access to non‑invasive cancer tests and advanced diagnostic services across the United States. The expansion reflects YD Bio’s commitment to translating innovative science into patient benefit while creating high‑quality local employment, Dr. Ethan Shen, Chairman and CEO of the Company, commented. “The Company will recruit scientific, regulatory and operational talent and will activate the site in phases, beginning with site selection and staffing, followed by staged commissioning of laboratory, manufacturing support and commercial functions to ensure a compliant and efficient ramp to full operations.” The Company will operate the California center through four strategic pillars: 1) Clinical & Regulatory Frontline Primary interface for FDA engagement, including pre‑IND/IDE interactionsSupport for clinical trial design, IRB coordination, and integration with U.S. health systemsReduction of time‑zone and regulatory friction to accelerate evidence generation 2) Market Access & Commercial Readiness Development of partnerships with U.S. providers, key opinion leaders (KOLs), and industry stakeholdersMarket education and early positioning for diagnostics, exosome programs, and cell therapiesEnablement of B2B licensing, collaborations, and strategic investment initiatives 3) Manufacturing & Supply Chain Interface Alignment with 3D Global Biotech’s U.S. GMP manufacturing investmentsCentral operations hub for prospective owned or acquired GMP facilitiesIntegration with U.S. CDMOs and establishment of scalable quality, productio...